Staff Members - Benha University
Focused low intensity shock wave therapy for management of benign prostatic hyperplasia :A Preliminary study
• 2021
Publication Information
Authors
A..Adel Abou-Taleb, W.S.Kandeel , A.A.Ali El-Shaer, K.M.Noah
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Objective: assess the effectiveness of shock waves in bph management by patients who do not
react to medical treatment Method and patients: This research is a prospective, non-randomized singlearm study at Benha University Hospital's Urology Department. This comprised (32) individuals with
BPH, with or without at least 6 months of poor response to pharmacological treatment by one or more
α-blockers, poor surgical candidates for co-morbidities or not interested in surgery. All patients
underwent six LISWT sessions once a week, and all patients were assessed by changes in IPSS,
QMAX, IIEF5, and PVRU at 3rd and 6th, and 3 months after treatment completion Results: substantial
improvement was seen in the maximal flow rate from9±1.50ml/sec before to sessions beginning to
13.9±1.2ml/sec, and also in PVR from 79.34±56.87ml to 55.43±35.65ml during the sixth week of
follow-up. The IPSS also improved substantially from 28±4.5 to 20.34±5 at the 6th week of follow-up.
Conclusion:LISWT is safe to use for BPH treatment particularly in non-respondent medical therapy
without severe side effects based on its antispasmodic characteristics.
react to medical treatment Method and patients: This research is a prospective, non-randomized singlearm study at Benha University Hospital's Urology Department. This comprised (32) individuals with
BPH, with or without at least 6 months of poor response to pharmacological treatment by one or more
α-blockers, poor surgical candidates for co-morbidities or not interested in surgery. All patients
underwent six LISWT sessions once a week, and all patients were assessed by changes in IPSS,
QMAX, IIEF5, and PVRU at 3rd and 6th, and 3 months after treatment completion Results: substantial
improvement was seen in the maximal flow rate from9±1.50ml/sec before to sessions beginning to
13.9±1.2ml/sec, and also in PVR from 79.34±56.87ml to 55.43±35.65ml during the sixth week of
follow-up. The IPSS also improved substantially from 28±4.5 to 20.34±5 at the 6th week of follow-up.
Conclusion:LISWT is safe to use for BPH treatment particularly in non-respondent medical therapy
without severe side effects based on its antispasmodic characteristics.